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Abstract
Background: Abnormal repeat length has been associated with an earlier age of onset and more severe disease progression
in the rare neurodegenerative disorder spinocerebellar ataxia 17 (SCA17).
Methodology/Principal Findings: To determine whether specific structural brain degeneration and rate of disease
progression in SCA17 might be associated with the CAG repeat size, observer-independent voxel-based morphometry was
applied to high-resolution magnetic resonance images of 16 patients with SCA17 and 16 age-matched healthy controls. The
main finding contrasting SCA17 patients with healthy controls demonstrated atrophy in the cerebellum bilaterally. Multiple
regression analyses with available genetic data and also post-hoc correlations revealed an inverse relationship again with
cerebellar atrophy. Moreover, we found an inverse relationship between the CAG repeat length and rate of disease
progression.
Conclusions: Our results highlight the fundamental role of the cerebellum in this neurodegenerative disease and support
the genotype-phenotype relationship in SCA17 patients. Genetic factors may determine individual susceptibility to
neurodegeneration and rate of disease progression.
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Introduction
The autosomal dominant spinocerebellar ataxias (SCA) are
clinically and genetically heterogeneous neurodegenerative disor-
ders. Twenty-eight genetic subtypes have been yet identified, of
which seven are caused by expansion of a CAG trinucleotid repeat
that encodes a polyglutamine tract in respective proteins [1]. A
longer CAG expansion may lead to an earlier onset [2] and a
more severe progression of clinical symptoms.
The rare neurodegenerative disorder SCA17 with mainly adult
age of onset is clinically highly variable manifesting with diverse
features including ataxia and dementia, extrapyramidal movement
and neuropsychiatric disorders, as well as seizures. Given the
extraordinarily broad clinical spectrum, SCA17 may mimic other
neurodegenerative disorders such as Huntington’s disease, Par-
kinson’s disease, and various other movement as well as cerebellar
disorders [3,4]. SCA17 is a progressive and irreversible neurode-
generative disorder.
Genetically, in the case of SCA17 the CAG pattern (CAG
trinucleotide repeat expansions) is repeated too many times,
and disrupts the normal function of the encoding protein, a
polyglutamine tract in the TATA-binding protein (TBP) gene [5]
on chromosome 6q27. The normal repeat range is from 25
up to 42–45 units [6]. Pathogenic repeats from 46 to 63 are
considered as expanded, whereas expansions from 43 to 48 CAG
repeats are regarded as intermediate alleles with reduced
penetrance [7] and CAG repeats from 49 to 66 as pathologic
alleles with complete penetrance.
Neuropathological examination in post mortem brain tissues
demonstrated cortical, subcortical, and cerebellar atrophy in
SCA17 [2,8]. At this, purkinje cell loss and gliosis, pseudohyper-
trophic degeneration of the inferior olive, marked neuronal loss
and gliosis in the caudate nucleus, and in the medial thalamic
nuclei were prominent features together with neuronal intranu-
clear inclusions stained with anti-TATA box-binding protein and
antipolyglutamine antibodies [8].
On the neuroanatomical level, MRI studies revealed predom-
inantly cerebellar atrophy among other brain structures in SCA17
patients [2,7,9,10].
To investigate whether the expansion of CAG repeats of the
TBP gene has an effect on the extent of brain atrophy in SCA17,
we correlated genetic findings with cerebral volume measures.
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Subjects
Sixteen SCA17 patients (mean age: 39.9612.6 (SD) years, 10
male) were recruited from the outpatient movement disorders
clinics at the Departments of Neurology of the Universities of
Rostock and Luebeck in Germany; where the patients have been
diagnosed and followed up on a regular basis. Total genomic DNA
was extracted from peripheral blood leucocytes by standard
protocols as described previously [5,7]. The number of CAG
repeats of the abnormal allele ranged from 44 to 55 triplets. The
age at onset varied from 18 to 47 years and the duration of
symptoms from 1 to 21 years (mean disease duration: 10.867.9
(SD) years). To measure the severity of ataxia, we used the
International Cooperative Ataxia Rating Scale (ICARS), (mean
ICARS score: 31.3625.5(SD)). Regarding to Netravathi and
colleagues, we defined patients’ clinical disease progression as the
quotient of the ICARS score divided by disease duration (ICARS/
DD) at the time of examination [19].
All subjects underwent a screening test for dementia, the
Mini-Mental State Examination Test (MMSE) [20]. Due to
motor impairment in some subjects resulting in incomplete
MMSE tests (e.g. drawing part), raw data were converted into
per cent ranges. Details of demographic and clinical data are
summarized in Table 1. Functional-morphological correlations
between motor and neuropsychiatric signs have been reported
before [9].
Sixteen age matched normal subjects (mean age: 40.75610.8
(SD) years, 9 male) were not related to the SCA17 subjects. The
following exclusion criteria were applied: a history of neurologic
or psychiatric illnesses, prior exposure to neuroleptic agents or
drug abuse, a medical history of hypertension, cardiovascular
disease, or diabetes mellitus. The study was approved by the
local ethics committee and written informed consent was
obtained from all participating subjects in accordance with the
Declaration of Helsinki [21] (http://www.wma.net/e/policy/b3.
htm).
MRI scanning and statistical analysis
All subjects underwent structural MRI imaging with a 1.5 T
whole-body scanner (Symphony, Siemens, Erlangen, Germany)
using a T1-weighted FLASH-3D MR sequence (echo time
[TE]=5 msec; repetition time [TR]=15 msec; flip angle=30u;
isotropic voxel size=16161m m
3).
MR images for all subjects were analyzed on a commercially
available Unix machine using a voxel-wise statistical approach.
Images were processed and analysed with Statistical Parametric
Mapping software (SPM5, Wellcome Department of Imaging
Neuroscience, Institute of Neurology, UCL, London, www.fil.ion.
ucl.ac.uk/spm) implemented in Matlab Version 7.6 (Mathworks,
Sherborn, MA, USA) and the VBM5 toolbox (http://dbm.neuro.
uni-jena.de/vbm). Applying a probabilistic framework, images
were registered using linear (12-parameter affine) and non-linear
transformations (warping), tissue classified, and bias corrected
within the same generative model [22]. The following analyses
were performed on gray matter segments that were multiplied by
the non-linear components derived from the normalization matrix
(modulated gray matter volumes). Finally, modulated gray matter
images were smoothed with a Gaussian kernel of 12 mm full width
at half maximum.
Using a general linear model, voxel-wise gray matter differences
between the patient group and the respective control group were
examined using independent-sample t-tests. To avoid possible
edge-effects around the border between gray and white matter or
cerebro-spinal fluid an absolute gray matter, threshold of 0.25
(absolute threshold masking) was used. For the statistical analysis,
we employed in the first step an uncorrected threshold of p,0.001
across the whole brain. In the second step, to explore the
association of regional brain volumes in SCA17 and length of the
expanded CAG repeats, we performed a multiple regression
analysis. The WFU PickAtlas [23] was used as an anatomical
reference to assess the exact localisation of gray matter changes.
Coordinates were reported in the standard anatomical space
developed at the Montreal Neurological Institute (MNI).
Table 1. Demographic and clinical data in SCA17 patients.
Number Sex Age (years) DD (years) Ataxia (ICARS) CAG Repeats MMSE(%)
1 M 34 20 59 52 96.7
2 M 42 7 9 51 100.0
3 W 28 7 51 55 89.3
4 M 46 19 50 54 50.0
5 M 42 3 0 49 96.7
6 M 40 5 4 51 100.0
7 W 66 21 41 46 60.7
8 W 22 1 36 44 100.0
9 W 45 20 59 54 75.0
10 W 54 7 54 51 60.7
11 W 50 18 71 45 13.3
12 M 51 20 44 54 33.3
13 M 23 4 3 54 100.0
14 M 34 16 18 49 100.0
15 M 20 2 0 54 100.0
16 M 42 2 1 49 96.7
Abbr.: DD, Disease Duration; ICARS, International Cooperative Ataxia Rating Scale; MMSE, Mini-Mental State Examination.
doi:10.1371/journal.pone.0015125.t001
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volumes were assessed by Pearson correlations. Post-hoc calcula-
tions and statistical analyses were performed on a Unix machine
and SPSS software package (SPSS v17.0, Chicago, Illinois, USA).
Given our hypotheses that the increase of the CAG repeat length is
associated with a decrease in gray matter volume or rather an
increase of the rate of disease progression, we used one-tailed
Pearson’ correlations for the post-hoc analysis. P-values of ,0.05
were considered significant.
Results
Cerebral atrophy and its relation to the abnormal CAG
repeat length in SCA17 patients
Compared to the healthy control group, in SCA17 patients the
largest cluster of gray matter volume reduction was found in the
bilateral cerebellum posterior lobe, (Table 2, Figure 1). The
regression analysis with the extended CAG repeats revealed a
highly significant negative correlation with grey matter reduction
in large parts of the cerebellum. The largest cluster of reduced gray
matter volume (kE=12257) was detected in the right anterior lobe
of the cerebellum extending to the other hemisphere, followed by
the second largest one (kE=4982) in the cerebellar posterior lobe
(Table 3, Figure 1).
Correlation of localized brain volume with clinical and
genetic parameters
Post-hoc Pearson correlations between the length of the
expanded CAG repeats and brain volumes showed a clear inverse
correlation with grey matter atrophy values in left posterior
(r=2.467, p=.034) and right posterior (r=.2691, p=.002) lobe
of the cerebellum (Figure 1B).
Furthermore, we performed a correlation to determine the
strength of the association between the expanded CAG repeat
length and disease duration (DD)-adjusted ataxia scores measured
by the ICARS (Ataxia/DD). By this, we found a significant inverse
Pearson’s correlation coefficient (r=2.492, p=.026) between the
CAG repeat length and rate of disease progression. Correlations
between other demographic or clinical data with the CAG repeat
length did not reveal significant results.
Discussion
Molecular neuroscience has clearly enhanced our pathobiolo-
gical understanding of neurodegenerative disorders. Investigating
a potential association of brain atrophy with genetic findings
represents an innovative way to unravel genotype-phenotype
relations in SCA17 patients. An observer-independent approach
revealed a significant inverse correlation between the expanded
size of CAG repeats and the extent of cerebral atrophy as well as
the rate of disease progression in patients with SCA17. These
findings might thus contribute to a better understanding of the
etiologic mechanisms underlying SCA17.
SCA17, inherited in an autosomal dominant manner, is caused
by an expanded CAG trinucleotide repeat in the TBP gene,
coding for glutamine. TBP, a general transcription factor, is an
essential component of the protein complex involved in RNA
synthesis with ubiquitous expression, including the central nervous
system [5]. Animal studies showed that complete loss of normal
TBP function is not compatible with life. Pathophysiologically, it is
thought that the neurodegenerative pathway is mediated by a toxic
gain of function of the expanded polyglutamine stretch [11].
Regarding other SCA subtypes such as SCA1, 2, 3, 6 and 7, it has
been reported that the CAG repeat size has not only a major effect
on the age of onset but also on the phenotypic expression and its
rate of progression [12]. Functional clinical measures correlated
with the CAG repeat length, more in SCA3 than in SCA1 [13].
The frequently found correlation between length of CAG tracts
and age of onset in polyglutamine disorders, could be also affirmed
for SCA17 [2,7].
On the neuroimaging level, there have been two earlier MRI
reports in SCA, one found a correlation of CAG repeat length
with one-dimensional or two-dimensional MRI measures of the
pons and cerebellar vermis in SCA3 patients [14], whereas the
other one failed to find a correlation between CAG repeat length
and normalized brain volume in SCA1, 2 and 3 [15]. However, a
large multicenter MRI study in SCA1, 3 and 6 revealed that
abnormal length of CAG repeats was associated with a decreased
brainstem, midbrain and putamen/caudate volume in SCA3, but
only mild with pons volume in SCA1 [13].
To our knowledge, this is the first study linking cerebral atrophy
and expanded CAG trinucleotid repeats in SCA17. MRI
characteristics in SCA17 include atrophy of the cerebellum,
cerebral cortex, brain stem and basal ganglia [8,9,16,17,18].
These studies also underlined the primary degeneration of
cerebellar structures. Clinical motor and neuropsychiatric corre-
lations demonstrated further the impact of the cerebellar
degeneration on the cerebro-cerebellar network [9]. Our findings
suggest that the rate of development of atrophy in the cerebellum,
which is most affected in SCA17, depends on the size of the CAG
Table 2. Categorical comparison of SCA17 patients and healthy controls.
Region Left hemisphere Right hemisphere
Coordinates Z-score kE Coordinates Z-score kE
xyz x y z
Cerebellum posterior lobe (VI) 216 280 212 4.47 24685 11 277 214 3.26 24685
Cerebellum posterior lobe (CrII) — — — — — 45 251 242 3.78 1074
Cerebellum anterior (R), posterior (L) lobe (VI) 228 266 230 3.57 24685 32 258 229 3.67 836
Caudate 212 20 24 4.43 940 11 18 21 4.19 773
Postcentral gyrus (BA 3,4) 248 227 41 3.78 439 48 224 40 4.70 1322
Postcentral gyrus (BA 40) — — 53 230 17 4.35 7582
Cingulate gyrus (BA 31) 213 241 40 4.08 3623 10 245 39 3.61 3623
doi:10.1371/journal.pone.0015125.t002
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PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e15125Figure 1. Grey matter changes and their correlation with CAG repeat size in SCA17 patients. A) Areas of grey matter volume reduction in
SCA17 patients compared with age-matched healthy controls (green) and regression analysis with the abnormal CAG repeat length in SCA17
(orange). The color bar represents the T-values. B) Pearson correlations between expanded CAG size and brain volume measures revealing an inverse
relationship with the left posterior (r=2.467, p=.034) and right posterior (r=.2691, p=.002) cerebellum.
doi:10.1371/journal.pone.0015125.g001
Table 3. Multiple regressions with abnormal CAG repeat length.
Region Left hemisphere Right hemisphere
Coordinates Z-score kE Coordinates Z-score kE
xyz x yz
Cerebellum anterior lobe (X) 223 237 235 3.43 12257 20 237 233 4.30 12257
Cerebellum anterior lobe (III) 25 242 228 4.12 65 4 241 226 3.95 764
Cerebellum posterior lobe (CrII) 236 258 244 4.25 12257 44 262 245 3.92 4982
doi:10.1371/journal.pone.0015125.t003
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PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e15125repeats. Numerous CAG repeats seem to induce faster cerebellar
atrophy and are therefore involved in the pathobiological progress
of neurodegeneration in SCA17. Although the exact pathophys-
iological underlying cellular mechanisms of the expanded CAG
repeats remains unknown and have to be elucidated in further
studies, our results emphasize the essential role of the cerebellum
and support the hypothesis of a distinct genotype-phenotype
relationship in the pathobiology of SCA17.
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